TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02472574

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YL-1 type of intracranial hematoma puncture needle
Description: YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: YL-1 type of intracranial hematoma puncture needle
Description: YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Up to 4 doses of 0.3\~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Up to 4 doses of 0.3\~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rt-PA
Description: Up to 4 doses of 0.3\~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
Study: NCT03073278

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.

Intervention type: RADIATION
Group type: OTHER
Intervention: Stereotactic Body Radiotherapy
Description: Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
Study: NCT03288597

Intervention type: RADIATION
Intervention: 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET
Description: At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT

Intervention type: RADIATION
Intervention: 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC
Description: At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
Study: NCT01828034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEK162
Study: NCT01686412

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic Fields of Low Energy (EEFLE)
Description: Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electromagnetic Fields of Low Energy (EEFLE)
Description: Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
Study: NCT01202825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
Study: NCT01920269

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-urethral resection
Description: Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical passive diffusion mitomycin
Description: A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravesical passive diffusion mitomycin
Description: A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: intravesical electromotive mitomycin
Description: A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
Study: NCT01748162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone IF needed
Study: NCT03028610

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: radiofrequency generator
Study: NCT04175028

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.

Intervention type: DEVICE
Group type: OTHER
Intervention: Transcranial Direct Current Stimulation
Description: In tDCS, electrodes are applied on the scalp to transmit direct current at low current amplitudes.
Study: NCT04998955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maximal strength training
Description: Exercise intervention utilizing 4 x 4 repetitions heavy resistance training
Study: NCT04311255

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia for the upper limb
Description: pecs-II block and intercostal nerve block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: regional anesthesia for the upper limb
Description: pecs-II block and intercostal nerve block
Study: NCT01202825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
Study: NCT04736238

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arthroscopy surgery
Description: The patient receives intraspinal anesthesia or general anesthesia under supine position. Establish an anteromedial channel at the inner side of the tibial anterior tibial tendon at the level of the tibiotalar joint, and establish an anterolateral channel at the lateral angle of the talus. Exploring and clearing the ankle joint and dealing with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then observe the lateral sulcus through the anterior medial channel, clean the synovium in the lateral sulcus, and explore the anterior talofibular ligament. A double-line anchor was inserted into the fibula side stop of the anterior talofibular ligament through the anterolateral channel. The anterior talofibular ligament was sutured using an outside-in technique in the anterior inferior safety zone of the distal end of the fibula. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: BrostrÖm surgery
Description: The patient receives intraspinal anesthesia or general anesthesia under supine position. The first ankle arthroscopy is performed to deal with possible combined injuries, such as talar cartilage injury, ankle impingement, and loose ankle joints. Then, open surgery was performed, and an arc incision was made at the anterior edge of the lateral malleolus to the tip of the fibula. After separating the subcutaneous tissue, the anterolateral joint capsule and talofibular ligament are exposed. A double-line anchor was placed at the fibular side stop of the anterior talofibular ligament. Tighten and suture the anterior talofibular ligament, anterolateral joint capsule, and extensor support belt with an anchor band. Fix the ankle joint with the suture after the dorsiflexion, neutral valgus position.
Study: NCT04576533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walk out from operating room
Description: After the surgery of laparoscopic colectomy or laparoscopic rectectomy surgery (Dixon technique), patients will be encouraged to walk out from the operating room and return to the ward by walking under the condition of stable physiological parameters, painlessness, clear consciousness and normal muscle strength of lower limb
Study: NCT01193907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197 12.5 mcg
Description: 1 dose of 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197 5.0 mcg
Description: 1 dose of 0.5 mL

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NVGH Vi-CRM197 1.25 mcg
Description: 1 dose of 0.5 mL

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vi-polysaccharide vaccine
Description: 1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
Study: NCT00062569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bathing Support Intervention (BSI)
Description: Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
Study: NCT00087516

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin - Rescue
Description: Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin - Rescue
Description: Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin - Rescue
Description: Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin - Rescue
Description: Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
Study: NCT00966888

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: No intervention

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Chest wall radiotherapy
Study: NCT04554199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible partial denture
Description: removable partial dentures (RPDs) were fabricated using thermoplastic resins (flexible RPDs). EEG and MMSE were evaluated before denture delivery and after one month of denture wear.
Study: NCT00062569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver reminiscence with coaching
Description: BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath
Study: NCT03001830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAV2/8-HLP-FVIII-V3
Description: Infusion of AAV2/8-HLP-FVIII-V3
Study: NCT04513925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1680 mg every 4 weeks (Q4W) will be administered IV on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiragolumab
Description: Tiragolumab 840 mg Q4W will be administered IV on Day 1 of each 28-day cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Durvalumab
Description: Durvalumab will be administered based on weight at 10 mg/kg IV every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle, or will be administered at a fixed dose of 1500 mg IV every 4 weeks (Q4W) (for participants whose weight \>/= 30 kg) on Day 1 of each 28-day cycle.
Study: NCT02568501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Description: Daily feedback on glucose levels from wireless glucometers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily feedback
Description: Daily feedback on glucose levels from wireless glucometers

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
Study: NCT01947010

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar 13

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pneumovax
Study: NCT01819012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.0 MAC
Description: 10 min-inhalation of each concentration of isoflurane, 1.0 MAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane 1.5 MAC
Description: 10 min-inhalation of each concentration of isoflurane, 1.5 MAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane 2.0 MAC
Description: 10 min-inhalation of each concentration of isoflurane, 2.0 MAC
Study: NCT02900157

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI9090
Description: MEDI9090 will be administered by IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab as a single agent will be administered by IV infusion after patients have completed the prescribed doses of Medi9090.
Study: NCT00685074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based Motivational Interviewing
Description: The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Time control
Description: A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
Study: NCT04031469

Intervention type: OTHER
Intervention: There is no intervention in this study
Description: There is no intervention in this study
Study: NCT03066011

Intervention type: DRUG
Intervention: Isavuconazonium sulfate
Description: Oral and Intravenous

Intervention type: DRUG
Intervention: Voriconazole
Description: Oral and Intravenous

Intervention type: DRUG
Intervention: Posaconazole
Description: Oral and intravenous
Study: NCT00806806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKY0402
Description: Local administration of SKY0402 followed by noxious stimulus

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Local administration of Placebo followed by noxious stimuli
Study: NCT01767649

Intervention type: OTHER
Intervention: Caesarean
Description: Collection of tissues and blood

Intervention type: OTHER
Intervention: Vaginal delivery
Description: Collection of tissues and blood
Study: NCT03446157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Loading dose on day 1 of week 1 of 400 mg/m2 via IV over 2 hours Subsequent doses of 250 mg/m2 via IV over 1 hour weekly for 4 weeks (28 days) in combination with palbociclib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: 125 mg taken orally once daily on days 1-21, then 7 days off
Study: NCT01319994

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin 850mg TDS (12 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 850mg TDS (12 weeks)
Study: NCT04079972

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: personalized lifestyle intervention
Description: Based on genotype of SNPs potentially relevant to weight control, tailored lifestyle guidance to facilitate weight loss will be provided.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: general lifestyle intervention
Description: Regardless of individuals' genetic make-up, general lifestyle guidance to facilitate weight loss will be provided.
Study: NCT03648073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]DOTATATE-PET/MRI
Description: \[68Ga\]DOTATATE-PET/MRI
Study: NCT04177901

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near infrared spectroscopy
Description: It is used for detection of tissue oxygenation
Study: NCT01039506

Intervention type: DRUG
Intervention: CPT-11 based regimens
Study: NCT05820880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed [Per/Ind/Aml]
Description: Fixed Dose combination of Perindopril/Indapamide/Amlodipine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Free [Per/Ind + Aml]
Description: Free dose combination of Perindopril/Indapamide and Amlodipine
Study: NCT02235207

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuromuscular exercise
Description: Fustra20 Neck \& Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.~The main targets are to~* improve movement control in different posture and movements of the neck and back~* improve flexibility with active functional movements~* improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain~* improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities
Study: NCT02332044

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdos
Description: capsule, 300mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talion
Description: tablet, 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdos, Talion
Description: capsule 300mg and tablet 10mg
Study: NCT04196959

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TYR sphere
Description: TYR sphere is a powdered protein substitute for patients with tyrosinaemia.
Study: NCT01588444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cortical FDBA
Description: cortical mineralized freeze-dried bone allograft

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cancellous FDBA
Description: CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)